Diagnostic and therapeutic challenges in chronic inflammatory demyelinating polyneuropathy and other immune-mediated neuropathies

Current Opinion in Critical Care

Volumn 17, Issue 2, 2011, Pages 101-105

  Magy, Laurent ^a   Mathis, Stéphane ^b   Vallat, Jean Michel ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

antimyelin associated glycoprotein antibodies; immune mediated neuropathy; multifocal motor neuropathy; polyradiculoneuropathy

Indexed keywords

CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GANGLIOSIDE GM1 ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEUKOCYTE ANTIGEN; METHOTREXATE; RITUXIMAB;

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DRUG MEGADOSE; FACIAL NERVE DISEASE; FOLLOW UP; GIANT AXONAL NEUROPATHY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; LONG TERM CARE; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; MOTOR NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY; MULTIFOCAL NEUROPATHY; MYELIN SHEATH; NERVE CONDUCTION; NERVE FIBER DEGENERATION; NEUROPATHIC PAIN; NEUROPATHY; OUTCOME ASSESSMENT; PLASMAPHERESIS; POLYNEUROPATHY; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; SENSORIMOTOR NEUROPATHY; TREATMENT FAILURE; TREATMENT RESPONSE;

FEMALE; HUMANS; MALE; PARAPROTEINEMIAS; POLYNEUROPATHIES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; TREATMENT OUTCOME;

EID: 79953077651     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e328342aded     Document Type: Review

References (51)

1. Uncini A, Manzoli C, Notturno F, et al. Pitfalls in electrodiagnosis of Guillain-Barre syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81:1157-1163.
2. Kokubun N, Nishibayashi M, Uncini A, et al. Conduction block in acute motor axonal neuropathy. Brain 2010;133:2897-2908.
3. Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010;74:1680-1686. This paper covers a crucial issue and provides important information for the management of patients with a Guillain-Barre-like onset.
4. Ruts L, Drenthen J, Jongen JL, et al. Pain in Guillain-Barre syndrome: a longterm follow-up study. Neurology 2010;75:1439-1447.
5. Martinez V, Fletcher D, Martin F, et al. Small fibre impairment predicts neuropathic pain in Guillain-Barre syndrome. Pain 2010;151:53-60.
6. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2010: CD002063.
7. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 2009;66:597-603. This paper is the first to show a relationship between prognosis in Guillain-Barre syndrome and the residual level of serum IgG after treatment with IVIg.
8. Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010;9:402-412.
9. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 2010;15:1-9. This is the first revision of the consensus criteria proposed by the European Federation of Neurological Societies and the Peripheral Nerve Society.
10. Isose S, Kuwabara S, Kokubun N, et al. Utility of the distal compound muscle action potential duration for diagnosis of demyelinating neuropathies. J Peripher Nerv Syst 2009;14:151-158.
11. Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010;15:50-56.
12. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009;8:158-164.
13. van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:245-253.
14. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 2005;31:663-680. (Pubitemid 40734675)
15. Erdmann PG, Lindeman E, Cats EA, et al. Functioning of patients with multifocal motor neuropathy. J Peripher Nerv Syst 2010;15:113-119.
16. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-78.
17. Pestronk A, Chuquilin M, Choksi R. Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside. J Neurol Neurosurg Psychiatry 2010;81:726-730. This paper provides new immunological markers of MMN.
18. Lambrecq V, Krim E, Rouanet-Larriviere M, et al. Sensory loss in multifocal motor neuropathy: a clinical and electrophysiological study. Muscle Nerve 2009;39:131-136.
19. Delmont E, Benaim C, Launay M, et al. Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition? J Neurol 2009;256:1876-1880.
20. van der Pol WL, Cats EA, van den Berg LH. Intravenous immunoglobulin treatment in multifocal motor neuropathy. J Clin Immunol 2010;30(Suppl 1): S79-S83.
21. Meuth SG, Kleinschnitz C. Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options. Eur Neurol 2010;63:193-204.
22. Paolazzi G, Peccatori S, Cavatorta FP, et al. A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis. Clin Rheumatol 2009;28:993-995.
23. *15 in patients with multifocal motor neuropathy. Neurology 2010;74:828-832.
24. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006;11:1-8.
25. Nobile-Orazio E, Terenghi F, Cocito D, et al. Oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy on chronic IVIg therapy. J Peripher Nerv Syst 2009;14:203-205.
26. Boerio D, Creange A, Hogrel JY, et al. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy. J Neurol Sci 2010;292:63-71.
27. Yuki N, Watanabe H, Nakajima T, et al. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2010. [Epub ahead of print] This paper provides further information on the mechanism of action of IVIg in MMN.
28. Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009;16:631-638.
29. Harbo T, Andersen H, Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology 2010;75:1377-1380.
30. Umapathi T, Hughes RA, Nobile-Orazio E, et al. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 2005: CD003217.
31. Stieglbauer K, Topakian R, Hinterberger G, et al. Beneficial effect of rituximab monotherapy in multifocal motor neuropathy. Neuromuscul Disord 2009;19:473-475.
32. Kelly JJ Jr, Kyle RA, O'Brien PC, et al. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981;31:1480-1483. (Pubitemid 12228290)
33. Kuijf ML, Eurelings M, Tio-Gillen AP, et al. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 2009;73:688-695.
34. Braun PE, Frail DE, Latov N. Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem 1982;39:1261-1265. (Pubitemid 13220379)
35. Hays AP, Latov N, Takatsu M, et al. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology 1987;37:242-256. (Pubitemid 17015497)
36. Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM antimyelin-associated glycoprotein. Ann Neurol 1993;33:502-506. (Pubitemid 23143034)
37. Chassande B, Leger JM, Younes-Chennoufi AB, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 1998;21:55-62. (Pubitemid 28041681)
38. Nobile-Orazio E. IgM paraproteinaemic neuropathies. Curr Opin Neurol 2004;17:599-605. (Pubitemid 39410876)
39. Smith IS. The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study. Brain 1994;117:949-957. (Pubitemid 24350531)
40. Kawagashira Y, Kondo N, Atsuta N, et al. IgM MGUS anti-MAG neuropathy with predominant muscle weakness and extensive muscle atrophy. Muscle Nerve 2010;42:433-435.
41. Vrethem M, Reiser N, Lauermann C, et al. Polyneuropathy associated with IgM vs IgG monoclonal gammopathy: comparison between clinical and electrophysiological findings. Acta Neurol Scand 2010;122:52-57.
42. Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710-717. (Pubitemid 30162720)
43. Niermeijer JM, Fischer K, Eurelings M, et al. Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study. Neurology 2010;74:406-412.
44. Vital A, Vital C, Julien J, et al. Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients. Acta Neuropathol 1989;79:160-167. (Pubitemid 19286142)
45. Kawagashira Y, Koike H, Tomita M, et al. Morphological progression of myelin abnormalities in IgM-monoclonal gammopathy of undetermined significance anti-myelin-associated glycoprotein neuropathy. J Neuropathol Exp Neurol 2010;69:1143-1157. A paper showing the temporal evolution of myelin damage in neuropathy associated with anti-MAG antibodies and providing new insights into the pathophysiology of this disorder.
46. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 1995;45:1577-1580.
47. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002;249:1370-1377. (Pubitemid 35217657)
48. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-489. (Pubitemid 36379372)
49. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003;27:611-615. (Pubitemid 36523521)
50. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM antimyelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65:286-293.
51. Vallat JM, Magy L, Richard L, et al. Intranervous immunoglobulin deposits: an underestimated mechanism of neuropathy. Muscle Nerve 2008;38:904-911. (Pubitemid 351915326)